NEW YORK , March 10, 2025 /PRNewswire/ -- Shareholder law firm Julie & Holleman LLP is investigating the proposed $4.10 per share sale of Checkpoint Therapeutics, Inc. (Nasdaq: CKPT) to Sun Pharmaceutical Industries, Inc. The firm is concerned about conflicts relating to Checkpoint's controlling shareholder, Fortress Biotech, Inc. (Nasdaq: FBIO), which has secured special benefits in the deal. For a free consultation, or to learn more, contact partner W.
Checkpoint Therapeutics (NASDAQ:CKPT) shares added more than 60% after it was revealed the immunology and targeted oncology firm will be acquired by Sun Pharmaceutical Industries. Under the agreement, Sun Pharma will acquire Checkpoint for $4.10 per share in cash, representing up to $355 million in upfront payments.
MILWAUKEE--(BUSINESS WIRE)--The Ademi Firm is investigating Checkpoint (Nasdaq: CKPT) for possible breaches of fiduciary duty and other violations of law in its transaction with Sun Pharma. Click here to learn how to join our investigation and obtain additional information or contact us at [email protected] or toll-free: 866-264-3995. There is no cost or obligation to you. In the transaction, Checkpoint stockholders will receive an upfront cash payment of only $4.10, without interest, and a n.
Will add UNLOXCYT™ (cosibelimab-ipdl), the first and only FDA-approved anti-PD-L1 treatment for metastatic or locally advanced cutaneous squamous cell carcinoma (cSCC) to Sun Pharma's global onco-derm franchise Will leverage Sun Pharma's global presence toaccelerate patient access to UNLOXCYT™ (cosibelimab-ipdl) Upfront cash payment of $4.10 per share of common stock,representing aggregate upfront consideration of up to $355 million Stockholders will also receive a contingent value right forup to $0.70 per share on achievement of a milestone Acquisition is subject to approval by Checkpoint's stockholdersand other customary closing conditions MUMBAI, India and WALTHAM, Mass., March 9, 2025 /PRNewswire/ -- Sun Pharmaceutical Industries Limited (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715 (together with its subsidiaries and/or associated companies, "Sun Pharma")) and Checkpoint Therapeutics, Inc. (Nasdaq: CKPT) ("Checkpoint") today announced that they have entered into an agreement by which Sun Pharma will acquire Checkpoint, an immunotherapy and targeted oncology company.
Checkpoint Therapeutics, Inc. received FDA approval for Unloxcyt, the first PD-L1 drug for advanced cSCC, with strong clinical results and a market-disruptive pricing strategy. Despite mixed investor reactions, Unloxcyt's potential $1.6B peak sales and competitive pricing could make it a transformative player in the cSCC market. Risks include high competition, commercialization costs, and potential IP challenges, but Checkpoint's strategic partnerships and marketing are crucial for success.
UNLOXCYT is the first and only FDA-approved anti-PD-L1 treatment for advanced cutaneous squamous cell carcinoma UNLOXCYT is the first and only FDA-approved anti-PD-L1 treatment for advanced cutaneous squamous cell carcinoma
Biologics License Application for cosibelimab under review by U.S. FDA PDUFA goal date of December 28, 2024 WALTHAM, Mass., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced financial results for the third quarter ended September 30, 2024, and recent corporate updates.
Biologics License Application currently under review by U.S. FDA; PDUFA goal date of December 28, 2024 Biologics License Application currently under review by U.S. FDA; PDUFA goal date of December 28, 2024
Checkpoint Therapeutics' Cosibelimab, an anti-PD-L1 antibody, shows promise for treating cSCC, with potential FDA approval by December 2024, making CKPT a speculative "buy." Cosibelimab's dual mechanism of action, engaging both T cells and NK cells, offers a competitive edge over other PD-L1 inhibitors, enhancing its efficacy. Despite CKPT's low cash reserves and regulatory risks, the potential market for Cosibelimab in cSCC treatment is estimated at over $1 billion in the US.
Checkpoint Therapeutics (CKPT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.